Skip to main content
AAO-HNSF 2023 Annual Meeting & OTO Experience Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Endocrine Surgery

Advanced Thyroid Cancer: State-of-the-Art Management

Monday, October 2, 2023
8:00 AM - 9:00 AM East Coast USA Time
Location: 202BC

    Moderator(s)

  • David C. Shonka, Jr., MD

    Associate Professor
    University of Virginia School of Medicine
    Charlottesville, VA, United States

    • Panelist(s)

  • GR

    Gregory W. Randolph, MD

    Professor
    Massachusetts Eye and Ear Infirmary Harvard
    Boston, MA, United States

  • Richard J. Wong, MD

    Chief, Head and Neck Service, Department of Surgery
    Memorial Sloan Kettering Cancer Center
    New York, NY, United States

  • Mark E. Zafereo, MD

    Professor, Head & Neck Surgery
    MD Anderson Cancer Center
    Houston, TX, United States

  • Lindsay A. Bischoff, MD

    Associate Professor of Medicine
    Vanderbilt University Medical Center
    Nashville, TN, United States

Disclosure(s):
David C. Shonka, MD, Jr.: No relevant relationships to disclose.
Richard J. Wong, MD: No relevant relationships to disclose.
Lindsay A. Bischoff, MD: No relevant relationships to disclose.
PROGRAM DESCRIPTION: Advanced thyroid cancer is often encountered by otolaryngologists specializing in head and neck surgery and endocrine surgery as well as by comprehensive otolaryngologists in the private practice setting. Management of patients with advanced thyroid cancer can be challenging and there have been substantial changes in the available treatment options in recent years. The first goal of this session is to define advanced thyroid cancer. The second goal is to discuss the preoperative evaluation of advanced thyroid cancer including the role of diagnostic imaging and molecular testing. The specific mutations that can be identified in thyroid cancer and the targeted and non-targeted treatment options that are available depending on the results of molecular testing will be reviewed. Finally, the session will cover aspects of surgical decision making and the role of neoadjuvant and postoperative adjuvant therapy.

This panel was presented at the 2022 Academy Meeting in Philadelphia. It was very well received and was given high scores by the audience. The organization of this one-hour session will mirror that of the 2022 panel. There will be a short introduction of key considerations in the management of thyroid cancer delivered by the panelists in a didactic format. The majority of the session will utilize multiple case presentations to illustrate state-of-the-art management of patients with advanced thyroid cancer. Case presentations of patients with advanced differentiated thyroid cancer, medullary thyroid cancer, and anaplastic thyroid cancer will be discussed. The main difference for the 2023 proposal is the inclusion of Dr. Bischoff as a panelist. As an endocrinologist with particular interest in the management of thyroid cancer and the Vice Chair of the NCCN Guidelines for Thyroid Cancer, her expertise in the endocrine aspects of advanced thyroid cancer management will be incredibly valuable.

OUTCOME OBJECTIVE 1: 1. Understand the definition of advanced thyroid cancer, specific driver mutations and targeted treatment options.

OUTCOME OBJECTIVE 2: 2. Understand the preoperative evaluation and intraoperative surgical considerations for advanced thyroid cancer.

OUTCOME OBJECTIVE 3: 3. Discuss the role of perioperative adjuvant therapy in the management of advanced thyroid cancer.

BACKGROUND STATEMENT: There is a need to summarize the management of advanced thyroid cancer in light of new developments in molecular testing, targeted treatment options, and surgical approach.